Diligence memo · auto-generated · as of July 2, 2026

Embold Health, Inc.

Embold Health, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Embold Health, Inc. operates in Healthtech, based in NASHVILLE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Embold Health, Inc. has raised $48M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $23M on 2021-12-03.

Most recent recorded round closed around 2021-12-03.

Valuation (modeled)modeled

Provath models Embold Health, Inc. at approximately $360M (range $54M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.80× the median modeled value of Series B Healthtech companies in 2019–2021 (56 peers) — value vs value, same stage and era. Within the normal band (80% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 7 months.

Last raise 4.6 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.9× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 90% of Healthtech peers (2138 compared).

Modeled value ranks above 91% of those peers.

Closest niche peers: Solera Health, Inc., Icebreaker Health, Inc., Buoy Health, Inc., Stroma Medical Corp, HealthJoy, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.